Skip to content

WSFS Financial WSFS Nonvested at end of year

Nonvested at end of year at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$37.56M-0.6%
WaFd, Inc. logo
WaFd, Inc.WAFD
827.8K-1.8%
Steven Madden logo
Steven MaddenSHOO
1.8M+5.2%
Lantheus Holdings logo
Lantheus HoldingsLNTH
1.2M-2.4%
Flagstar Bank
 logo
Flagstar Bank FLG
2.8M-59.3%
International Paper logo
International PaperIP
5.4M-21.8%

Other financials

Income statement

See full
Revenue$275.3M+7.5%
Net income$86.8M+31.8%
EPS (diluted)$1.64+46.4%

Balance sheet

See full
Cash & equivalents$2.5B+143%
Total debt$129.6M-15.1%
Total equity$2.7B+2.0%
Total assets$22.1B+7.6%

Cash flow

See full
Operating cash flow$86.4M+888%
CapEx$885.0K-63.6%
Free cash flow$85.5M+1,254%

Valuation

See full
Market cap$3.96B+13.6%

Profitability

See full
Net margin28.4%+3.3pp
FCF margin27%+17.1pp

Returns & leverage

See full
Return on equity11.4%+1.2pp
Debt / equity0.0×

Where this comes from

Reported directly by WSFS Financial in its filing.

Tagged under the XBRL concept wsfs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue.

The official record: WSFS Financial’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about WSFS Financial's nonvested at end of year.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WSFS Financial's nonvested at end of year?
WSFS Financial (WSFS) reported nonvested at end of year of $0 in Q4 2025.
How has WSFS Financial's nonvested at end of year changed year-over-year?
WSFS Financial's nonvested at end of year decreased by 100.0% year-over-year, from $19K to $0.
What is the long-term trend for WSFS Financial's nonvested at end of year?
Over 5 years (2020 to 2025), WSFS Financial's nonvested at end of year has grown at a -100.0% compound annual growth rate (CAGR), from $1.51M to $0.
What does nonvested at end of year mean?
This represents the total count of outstanding share-based payment awards that remain unvested at the conclusion of the fiscal year. It is a key indicator of the company's ongoing human capital investment and the volume of potential future shares that may be issued. Tracking this figure helps analysts model future share count dilution and compensation expense.